Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Comprehensive review of cell migration

Cell migration is a highly complex process which involves several compartments of the cell, including surface receptors, signalling elements and the cytoskeleton.

23 Dec 2009

UPMC reports 10,000th patient treated using Elekta's Leksell Gamma Knife system

On the morning of December 17, 2009, UPMC physicians used Gamma Knife® surgery to treat the center's 10,000th patient, an 81-year-old male with a tumor deep in his brainstem, a site where traditional surgery would have been impossible. Gamma Knife surgery is performed using Elekta's Leksell Gamma Knife system, which directs up to 201 pencil-thin beams of therapeutic radiation precisely on brain tumors and other targets in the head.

From Elekta 23 Dec 2009

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

Researchers follow steps that lead some tumor cells to establish metastases

Up to 25% of cancer patients develop metastases in the brain - often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious.

21 Dec 2009

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians.

17 Dec 2009

Silence Therapeutics and Intradigm merge to form RNAi

The Boards of Silence Therapeutics plc and Intradigm Corporation are delighted to announce the merger of their businesses to form a leading company in the field of RNAi (RNA interference).

17 Dec 2009

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Aided by next-generation DNA sequencing technology, an international team of researchers has gained insights into how more than 60 carcinogens associated with cigarette smoke bind to and chemically modify human DNA, ultimately leading to cancer-causing genetic mutations.

17 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

New brain metastases treatment guidelines

New treatment guidelines for patients with brain metastases are now available from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS).

10 Dec 2009

Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement

Pro-Pharmaceuticals, Inc., today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $4.4 million.

10 Dec 2009

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

10 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

Discovery may lead to new treatments for late-stage breast cancer

Researchers from the Indiana University School of Medicine and colleagues at the University of Texas Southwestern and Case Western University have determined how the protein Mdm2, which is elevated in late-stage cancers, disables genes that suppress the growth of tumors. The finding may lead to the development of new drugs for late stage breast cancer and other difficult to treat malignancies.

8 Dec 2009

Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug

Galapagos NV (Euronext: GLPG) announced today that it has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK).

8 Dec 2009

Long-chain omega-3 fatty acids can prevent colorectal cancer

Long-chain omega-3 fatty acids, primarily found in fish and seafood, may have a role in colorectal cancer prevention, according to results presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9, 2009, in Houston.

8 Dec 2009

Galapagos NV issues new shares

Galapagos NV (Euronext: GLPG) announced today a capital increase of EUR 902,564 and the issue of 225,641 new shares as a result of the exercise of warrants by Galapagos warrant holders, including CEO Onno van de Stolpe.

7 Dec 2009

TGFb growth factor controls spread of cancer cells

The spread, or metastasis, of individual breast cancer cells from the main tumor into the blood circulation to the lungs and other body tissues and organs is under the control of a growth factor abbreviated TGFb, according to a study with laboratory mice that will be presented at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009